MeSH Browser

MeSH Heading: Zidovudine
Tree Number(s): D03.383.742.680.705.950; D13.570.230.500.950; D13.570.230.855.950; D13.570.685.705.950
Unique ID: D015215
RDF Unique Identifier: http://id.nlm.nih.gov/mesh/D015215
Scope Note: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.
Entry Term(s): 3'-Azido-2',3'-Dideoxythymidine; 3'-Azido-3'-deoxythymidine; AZT (Antiviral); AZT Antiviral; AZT, Antiviral; Azidothymidine; BW A509U; BWA-509U; Retrovir
Pharm Action: Antimetabolites
Reverse Transcriptase Inhibitors
Anti-HIV Agents
Related Numbers: 30516-87-1
CAS Type 1 Name: Thymidine, 3'-azido-3'-deoxy-
Previous Indexing: Thymidine/analogs & derivatives (1975-1988)
Public MeSH Note: 89
History Note: 89
Date Established: 1989/01/01
Date of Entry: 1988/05/09
Revision Date: 2016/06/01

Allowable Qualifiers: administration & dosage (AD)

adverse effects (AE)

agonists (AG)

analogs & derivatives (AA)

analysis (AN)

antagonists & inhibitors (AI)

blood (BL)

cerebrospinal fluid (CF)

chemical synthesis (CS)

chemistry (CH)

classification (CL)

economics (EC)

history (HI)

immunology (IM)

isolation & purification (IP)

metabolism (ME)

pharmacokinetics (PK)

pharmacology (PD)

poisoning (PO)

radiation effects (RE)

standards (ST)

supply & distribution (SD)

therapeutic use (TU)

toxicity (TO)

urine (UR)

Concept UI: M0023377
Related Numbers: 30516-87-1
Scope Note: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.
Terms: Zidovudine Preferred Term
Term UI T044495
Date01/01/1999
LexicalTag NON
ThesaurusID; Azidothymidine
Term UI T044490
Date05/09/1988
LexicalTag NON
ThesaurusID; AZT Antiviral
Term UI T044491
Date05/09/1988
LexicalTag NON
ThesaurusID UNK (19XX); 3'-Azido-2',3'-Dideoxythymidine
Term UI T044489
Date05/09/1988
LexicalTag NON
ThesaurusID UNK (19XX); AZT (Antiviral)
Term UI T044493
Date05/09/1988
LexicalTag NON
ThesaurusID UNK (19XX); 3'-Azido-3'-deoxythymidine
Term UI T044497
Date07/13/1995
LexicalTag NON
ThesaurusID; AZT, Antiviral
Term UI T044492
Date05/09/1988
LexicalTag NON
ThesaurusID UNK (19XX)

Zidovudine MeSH Descriptor Data 2024